http://www.investingdaily.com/res/reports/term1y/PCA-Make_Up_to_48x_Your_Money_Riding_the_$3.5_Trillion_Beacon_Gold_Rush.pdf

I am not familiar with that Investing Daily promo, so can you copy & paste it into a reply to this message so I can figure out which one of our services to refer you to? Thank you.

The only IoT stock currently held in the Breakthrough Tech portfolio is Silicon Labs (SLAB), which is up about 20% since Ben first recommended it three months ago. We still recommend it, and are also researching a couple of other names, including some small and mid-cap stocks, in the IoT space to recommend, and will publish them as soon as we determined which one(s) meet our requirements. Thank you.

I’m sorry, but I can’t help you. That’s an ad from one of our competitors, not us.

Yes, in fact Ben is writing an update on FEYE in today’s issue of BTW so please be on the lookout for it. Thank you.

http://www.investingdaily.com/res/reports/term1y/PCA-Make_Up_to_48x_Your_Money_Riding_the_$3.5_Trillion_Beacon_Gold_Rush.pdf

As we reported a couple of weeks ago (http://www.investingdaily.com/breakthrough-tech-profits/articles/28503/argos-raises-more-money/), thus far there is no data or news that undermines our fundamental thesis for owning ARGS, which is eventual FDA approval of its cancer immunotherapy treatment so we continue to recommend owning it. If you already own it, then may want to use current price weakness to average down your cost. And if you don’t yet own it, now would be a good time to buy it.

There has been no press releases from Argos since its quarterly earnings report two weeks ago, nor has any analyst that follows the company changed their recommendation on it so there is nothing new as far as we know.

Be careful with this one, a lot of class action lawsuits have been filed against Concordia that appear to have some merit. Its share price has dropped so much that at some point it may get a “dead cat bounce”, but other than that I don’t see much profit potential in the near term.

Hi Lyubov. I’m not familiar with a document by that name, so can you tell which publication it is associated with to help me find it for you? Thank you.

I am not involved with that aspect of the publication, so for that information you need to talk to our customer service department at 1-800-832-2330. Thank you.

Hi Buck. Yes it is, and I just wrote an update on it last week that should get you up to date on where things stand with the company (http://www.investingdaily.com/breakthrough-tech-profits/articles/28696/argos-confirms-expansion-plans/). Thank you.

Hi James. You should have received our special report on cancer immunotherapy (which can be found under the Resources tab at the top of this page in case you did not: http://www.investingdaily.com/res/reports/term1y/BTP-One_Little_Shot_to_Kill_Cancer_Dead.pdf), which identifies Argos Therapeutics (ARGS) as hat “alpha cells” stock. I also wrote an update on it last week (http://www.investingdaily.com/breakthrough-tech-profits/articles/28696/argos-confirms-expansion-plans/) to bring you fully up to date on where things stand at the moment. Thank you.

Hi Lucille. We do not actively follow PLAB, so my familiarity with the company is limited. But from taking a quick look at it, I don’t see any reason to think that the stock is about to jump. The good news is the company is profitable and is trading at a reasonable forward P/E multiple (15x), but the bad news is its top line revenue is shrinking as the PC market wanes and it has a high debt/equity ratio (8.4). That said, if you are looking for a reason to be optimistic, its book value is nearly a dollar higher than its share price ($10.39 vs. 9.55)., suggesting that it could be taken private or acquired for a quick 10% gain.